Ignite Creation Date:
2025-12-25 @ 2:22 AM
Ignite Modification Date:
2025-12-27 @ 11:29 PM
Study NCT ID:
NCT01196234
Status:
COMPLETED
Last Update Posted:
2013-01-29
First Post:
2010-08-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D017239', 'term': 'Paclitaxel'}, {'id': 'C053518', 'term': 'CP protocol'}], 'ancestors': [{'id': 'D043823', 'term': 'Taxoids'}, {'id': 'D043822', 'term': 'Cyclodecanes'}, {'id': 'D003516', 'term': 'Cycloparaffins'}, {'id': 'D006840', 'term': 'Hydrocarbons, Alicyclic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D004224', 'term': 'Diterpenes'}, {'id': 'D013729', 'term': 'Terpenes'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 84}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2009-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-01', 'completionDateStruct': {'date': '2012-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2013-01-28', 'studyFirstSubmitDate': '2010-08-09', 'studyFirstSubmitQcDate': '2010-09-07', 'lastUpdatePostDateStruct': {'date': '2013-01-29', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2010-09-08', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2012-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Response Rate', 'timeFrame': 'average 6 months'}], 'secondaryOutcomes': [{'measure': 'progression free survival', 'timeFrame': 'average 2 years'}, {'measure': 'overall survival', 'timeFrame': 'average 2 years'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Non Small Cell Lung Cancer']}, 'referencesModule': {'references': [{'pmid': '26493267', 'type': 'DERIVED', 'citation': 'Choi YJ, Lee DH, Choi CM, Lee JS, Lee SJ, Ahn JH, Kim SW. Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naive non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. BMC Cancer. 2015 Oct 22;15:763. doi: 10.1186/s12885-015-1714-y.'}]}, 'descriptionModule': {'briefSummary': 'This study compares paclitaxel/carboplatin (PC) to PC chemotherapy followed by gefitinib for 2 weeks in patients with Non-small Cell Lung Cancer (NSCLC) without epidermal growth factor receptor (EGFR) mutations.\n\nExpanded acronym : \\[P\\]aclitaxel/Ca\\[r\\]boplatin (PC) followed by Gef\\[i\\]tinib in A\\[d\\]vanc\\[e\\]d Non-small Cell Lung Cancer (NSCLC): Randomized phase II study.', 'detailedDescription': 'A randomized phase II trial that compares paclitaxel/carboplatin (PC) to PC chemotherapy followed by gefitinib for 2 weeks in patients with NSCLC without EGFR mutations. While previous studies with cytotoxic agents and gefitinib failed to show any benefit, we altered the schedule of administration in hopes to gain synergy between agents.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* More than 18 years of age\n* Histologically documented non-small cell lung cancer with metastasis (Stage IV) or locally advanced (Stage IIIB) with malignant effusion.\n* At least 1 measurable lesion as defined by RECIST1.0. All target lesions must have a unidirectional diameter of at least 1cm. Baseline measurements must be compared within 4 weeks prior to enrollment.\n* ECOG PS 0-2\n* At least 1 week since the last radiotherapy. Patients must have recovered from all acute toxicities from radiotherapy.\n* Patients must have adequate hematologic, renal and liver function as defined by Hb \\> 9g/dL, neutrophils \\> 1000/mm3, platelets \\> 50,000/mm3, creatinine \\< 2mg/dL, and AST (SGOT) and/or ALT (SGPT) \\< 5 x UNL (upper normal limit).\n* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.\n* Written and voluntary informed consent understood, signed and dated.\n\nExclusion Criteria:\n\n* Patients with tumor harboring EGFR mutation.\n* Prior systemic therapy for NSCLC\n* Non-smoking patients with adenocarcinoma. But if those patients show wild type EGFR, they are eligible to this study.\n* Symptomatic brain metastasis. Brain metastases stable \\< 2 weeks before dosing or requiring concurrent steroid treatment or with clinical symptoms.\n* Major surgery within 3 weeks prior to study enrollment.\n* Previous (less than 3 years ago) or current malignancies at sites other than curatively treated in situ carcinoma of cervix, or basal or squamous cell carcinoma of the skin.\n* Severe medical illness or active infection that would impair the ability to receive gefitinib.\n* Pregnancy or breast feeding.'}, 'identificationModule': {'nctId': 'NCT01196234', 'acronym': 'PRIDE', 'briefTitle': 'Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer', 'organization': {'class': 'OTHER', 'fullName': 'Asan Medical Center'}, 'officialTitle': 'Paclitaxel/Carboplatin (PC) Followed by Gefitinib or Paclitaxel/Carboplatin (PC) in Advanced Non-small Cell Lung Cancer (NSCLC): Randomized Phase II Study', 'orgStudyIdInfo': {'id': 'AMC 2009-0677'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Paclitaxel/Carboplatin/Gefitinib', 'description': 'Paclitaxel/Carboplatin/Gefitinib', 'interventionNames': ['Drug: Paclitaxel/Carboplatin/Gefitinib']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Paclitaxel/Carboplatin', 'description': 'Paclitaxel/Carboplatin', 'interventionNames': ['Drug: Paclitaxel/Carboplatin']}], 'interventions': [{'name': 'Paclitaxel/Carboplatin/Gefitinib', 'type': 'DRUG', 'description': 'paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)/daily gefitinib 250mg/day during day 2-15', 'armGroupLabels': ['Paclitaxel/Carboplatin/Gefitinib']}, {'name': 'Paclitaxel/Carboplatin', 'type': 'DRUG', 'description': 'paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)', 'armGroupLabels': ['Paclitaxel/Carboplatin']}]}, 'contactsLocationsModule': {'locations': [{'zip': '138-736', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Asan Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}], 'overallOfficials': [{'name': 'Sang-We Kim, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Asan Medical Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Asan Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'AstraZeneca', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor', 'investigatorFullName': 'Sang-We Kim', 'investigatorAffiliation': 'Asan Medical Center'}}}}